Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.